Intrommune Reports Positive Update from Ongoing Phase 1 Study in Peanut Allergy
INT301 Met Safety Goals Across Four Dose Levels in Cohort 1 Patient Treatment Now Ongoing…
News
Vistin Pharma ASA: Invitation to Q4 2021 conference call
Oslo, Norway, 8 February 2022 Vistin Pharma ASA will release its fourth quarter 2021 results…
Eyenovia Concludes Type A Meeting with FDA Related to MydCombi™ NDA Resubmission
No additional clinical work required; NDA resubmission anticipated in Q3 2022 NEW YORK, Feb. 08,…
Healx and Ovid Therapeutics to Enter Strategic Partnership
– Ovid to License Gaboxadol to Healx – – Healx to Explore Gaboxadol in Combination…
NextCure to Present at 11th Annual SVB Leerink Global Healthcare Conference
BELTSVILLE, Md., Feb. 08, 2022 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical…
Beyond Air® Announces Participation at Upcoming Investor Conferences in March 2022
GARDEN CITY, N.Y., Feb. 08, 2022 (GLOBE NEWSWIRE) — Beyond Air, Inc. (NASDAQ: XAIR), a…
Soleno Therapeutics to Participate in the BIO CEO & Investor Conference
REDWOOD CITY, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) — Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO),…
Salarius Pharmaceuticals to Participate in the 2022 BIO CEO & Investor Conference
HOUSTON, Feb. 08, 2022 (GLOBE NEWSWIRE) — Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical…
Palisade Bio (Nasdaq: PALI) to Announce Adhesions Clinical Data at SAGES 2022 Annual Meeting
Incidence and Severity of Post-Surgical Intraabdominal Adhesions following Bowel Resection Surgery and Treatment with Enteral…
Frontier Medicines Announces Renowned Physician Scientist Piro Lito, M.D., Ph.D., Joins Scientific Advisory Board
SOUTH SAN FRANCISCO, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) — Frontier Medicines Corporation, a precision…
GelStat Announces $5 Million Public Offering Under Regulation A+
GelStat Corporation Has Been Qualified by the SEC for a Regulation A+ Public Offering STUART,…
Akero Therapeutics Completes Enrollment of Phase 2b HARMONY Study in Pre-Cirrhotic NASH Patients
SOUTH SAN FRANCISCO, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) — Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage…
Werewolf Therapeutics to Present at the SVB Leerink Global Healthcare Conference
CAMBRIDGE, Mass., Feb. 08, 2022 (GLOBE NEWSWIRE) — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”)…
Ocuphire Completes Enrollment in MIRA-3 Pivotal Phase 3 Clinical Trial for Nyxol® in RM and Announces Two Upcoming Medical Conference Presentations
Completed enrollment ahead of schedule in second Phase 3 FDA registration trial for Nyxol in…
Recce Pharmaceuticals Announces Positive Safety Data from Third Cohort of Phase I Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327
Highlights: Seven subjects in cohort three intravenously dosed; RECCE® 327 at 500mg indicating to be…
Noema Pharma to Host Key Opinion Leader Webinar on Trigeminal Neuralgia “Trigeminal Neuralgia? You are not alone”
Friday, February 11th 2012 – 12 pm EST / 6 pm CET Featuring Dr. Joanna…
Aleafia Health to Announce Fourth Quarter 2021 Results
TORONTO, Feb. 08, 2022 (GLOBE NEWSWIRE) — Aleafia Health Inc. (TSX: AH, OTCQX: ALEAF) (“Aleafia…
Oculis appoints Dr. Bastian Dehmel as Chief Development Officer
Oculis appoints Dr. Bastian Dehmel as Chief Development Officer Former Amgen Global Development Leader/OxThera CMO…
InflaRx to Present at Annual SVB Leerink Global Health Conference
JENA, Germany, Feb. 08, 2022 (GLOBE NEWSWIRE) — InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical…
Cognition Therapeutics to Participate in Panel during the BIO CEO & Investor Conference on the Development of Neurodegenerative Therapeutics
Anthony Caggiano, M.D., Ph.D., Participating on February 15th Panel: “Exploring the Possibilities of Developing Neurodegenerative…